List view / Grid view
21 April 2017 | By Niamh Marriott, Junior Editor
Taking cannabidiol may cut seizures in half for some children and adults with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy...
17 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The Ministry has publicly expressed interest in bringing Cannabis research to Colombia and the Company feels their project is in line with this aspiration...
21 June 2016 | By Victoria White, Digital Content Producer
GW Pharmaceuticals has selected infantile spasms as the fourth target indication for its Epidiolex orphan paediatric epilepsy development programme...
11 April 2016 | By Victoria White, Digital Content Producer
TSC is the third indication that GW is targeting with Epidiolex, which includes four Phase III trials in Dravet syndrome and Lennox-Gastaut syndrome...
14 March 2016 | By Victoria White
Epidiolex achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with placebo...
15 September 2015 | By Victoria White
The addition of Cannabidiol (CBD)to the medication of patients who were only partially responsive to standard treatment produced significant improvements in outcome measures...
12 May 2015 | By Victoria White
GW Pharmaceuticals has commenced a Phase 3 clinical trial of Epidiolex (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS)...
22 April 2015 | By Victoria White
GW Pharmaceuticals has initiated the second Phase 3 clinical trial of Epidiolex for the treatment of Dravet syndrome, a rare form of childhood epilepsy...
